## UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 11, 2010

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

OncoGenex Pharmaceuticals, Inc.

File No. 33-80623 - CF#24826

OncoGenex Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 8, 2010.

Based on representations by OncoGenex Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.37	through July 2, 2018
Exhibit 10.40	through November 10, 2018
Exhibit 10.44	through March 31, 2014

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel Greenspan Special Counsel